ReviewRSC advances2026
Empowering women's health with miRNA-integrated nanochemical approaches: from reproductive health to cancer care.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs), a category of small (18-25 nucleotides) non-coding transcripts that modulate gene expression at the post-transcriptional level, are necessary for regulatory processes in female reproduction, specifically in ovarian function and follicular development. Dysregulation of these miRNAs is implicated in reproductive disorders like PCOS, endometriosis, and gynecological cancers. Nanotechnology in medicine encompasses the study of the properties and uses of nanomaterials to enable the development of more precise therapeutic techniques, including biosensing and diagnostics, targeted medication delivery, and tissue engineering. In this review, the recent advancements in utilizing nano-based technologies accompanied by miRNAs, including polymeric nanostructures, metallic nanoparticles (NPs), extracellular vesicle (EV) mimetics, DNA-based nanostructures, and lipid-based nanostructures, to treat conditions like endometriosis and PCOS or breast, cervical, and ovarian cancers and their limitations are discussed. Despite the reported improvements, clinical translation is hampered by challenges related to long-term stability, scalability, and immune recognition. Future research should focus on improving hybrid nanocarrier systems and miRNA-based precision medicine to improve treatment outcomes for women's health.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.